Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial
- 24 July 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 326-333
- https://doi.org/10.1016/j.clcc.2021.07.006
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2015
- Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocolBMJ Open, 2015
- The beneficial effect of palliative resection in metastatic colorectal cancerBritish Journal of Cancer, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Curable Metastatic Colorectal CancerCurrent Oncology Reports, 2011
- Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolitesCancer Research, 2010
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Sex is a major determinant of CYP3A4 expression in human liverJournal of Hepatology, 2003
- Sex is a major determinant of CYP3A4 expression in human liverJournal of Hepatology, 2003